Peptides for libido: what the evidence actually supports

What did @alisa_frierson actually say?

In this reply video, the creator outlines a dosing framework for what is almost certainly PT-141 (bremelanotide), the peptide most commonly associated with libido discussions in this space. She suggests "anywhere between 0.5 and 2 milligrams per week," describes two administration styles, a divided low-dose approach for "a more steady state of effect" versus a single higher dose timed to lifestyle, and briefly acknowledges that factors like height, weight, and age can influence dosing. She frames this as clinical customization, not a blanket protocol. That framing matters, and we'll get into why it's both the strongest and weakest part of her claims.

She does not name the specific peptide in this clip, which is a significant omission. Viewers responding to a question about libido peptides may reasonably assume she is discussing PT-141, but without confirmation, the dosing figures are floating without an anchor. That ambiguity is a real problem when social media audiences are self-dosing from incomplete information.

Does the science back this up?

For PT-141 specifically, the evidence is more substantial than most peptides discussed on TikTok, but it does not cleanly support the subcutaneous weekly dosing framework she describes. The FDA approved bremelanotide (Vyleesi) in 2019 for hypoactive sexual desire disorder in premenopausal women, as an intranasal or subcutaneous injection taken as needed, not on a weekly cumulative schedule.

The pivotal trials, including Clayton et al. (2016, Journal of Sexual Medicine) and Simon et al. (2014, Journal of Sexual Medicine), tested single as-needed doses of 1.25 mg or 1.75 mg subcutaneously, not divided weekly protocols. There is no peer-reviewed literature that establishes a "steady state" pharmacological rationale for splitting PT-141 into smaller doses across a week. Melanocortin receptor agonists like PT-141 work acutely, not through receptor saturation over days. The steady-state framing she uses is pharmacologically more appropriate for hormones or peptides with longer half-lives, like GnRH analogs or testosterone. Applied here, it is not well-supported.

What did they get wrong (or right)?

She gets partial credit for acknowledging individual variability. Height, weight, and age do influence peptide pharmacokinetics in real ways, and the honest disclosure that dosing "can be customized" is a more responsible message than the flat "take 2 mg" instructions common in this space.

Where she goes wrong is the "steady state of effect" claim for divided dosing. PT-141 has a half-life of roughly 2.7 hours (Pfaus et al., 2007, Annals of the New York Academy of Sciences). Spreading doses across a week does not produce steady-state plasma levels in any clinically meaningful sense. If she is discussing a different peptide entirely, she should have named it. Without that context, the pharmacological logic she offers does not hold up.

The 0.5 to 2 mg range is broadly consistent with clinical trial doses, but the weekly framing misrepresents how the drug behaves in the body. That is not a small technical error. It shapes how viewers understand the mechanism, and it could lead someone to time doses incorrectly.

What should you actually know?

If you are considering any peptide that affects sexual desire, a few things are worth understanding before you take dosing advice from a short-form video, regardless of who made it.

• PT-141 is the only melanocortin-based peptide with FDA approval data behind it. Compounded versions are not equivalent to Vyleesi in terms of regulatory oversight or verified purity.
• The approved as-needed dosing model (single injection before anticipated activity) has more clinical support than weekly divided dosing schedules circulating online.
• Side effects from PT-141 trials included nausea, flushing, and transient blood pressure increases (Simon et al., 2014). These are not trivial, particularly in people with cardiovascular risk factors.
• "Customization" is only meaningful when it comes from a provider who has reviewed your full medical history, not a general social media framework applied to an unnamed peptide.
• No peptide discussed in telehealth or wellness contexts should be treated as a treatment or cure for sexual dysfunction disorders. These are regulated medical conditions requiring proper diagnosis.

The creator's overall tone is measured relative to what circulates in this space. But measured is not the same as accurate, and the missing peptide name plus the flawed steady-state rationale are real gaps that matter when people are making decisions about injection protocols based on this content.